Trial ID or NCT#



not recruiting iconNOT RECRUITING


This 2-part, phase 1/2 trial examines the side effects of cancer immunotherapy with CRS-207 alone and in combination with epacadostat (INCB024360), an indoleamine 2,3-dioxygenase (IDO1) inhibitor, and to see how well they work in treating patients with ovarian, fallopian tube, or peritoneal cancer who progressed on a platinum-based chemotherapy within 6 months. CRS-207 is a weakened (attenuated) form of Listeria monocytogenes that has been genetically modified to reduce its ability to cause disease, while maintaining its ability to stimulate potent immune response to kill tumor cells. Epacadostat is a potent, highly selective IDO1 inhibitor which stimulates immune cell activation in tumors.

Official Title

A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No


Oliver Dorigo, M.D., Ph.D.
Oliver Dorigo, M.D., Ph.D.
Gynecologic oncologist, Medical oncologist, Gynecologic oncologist
Associate Professor of Obstetrics and Gynecology (Oncology)
Jonathan S. Berek, MD, MMSc
Jonathan S. Berek, MD, MMSc
Gynecologic oncologist
Laurie Kraus Lacob Professor
Amer Karam
Amer Karam
Gynecologic oncologist, Medical oncologist, Obstetrician and Gynecologist (OB-GYN)
Clinical Professor, Obstetrics & Gynecology - Gynecologic Oncology

Contact us to find out if this trial is right for you.


Aarti Kale
(650) 723-0622